Compare ACHR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACHR | GPCR |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | 233 |
| Industry | Aerospace | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2020 | 2023 |
| Metric | ACHR | GPCR |
|---|---|---|
| Price | $6.61 | $54.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $12.00 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 41.0M | 516.8K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | $4,986.67 | N/A |
| Revenue Next Year | $876.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.30 | $18.26 |
| 52 Week High | $14.62 | $94.90 |
| Indicator | ACHR | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 62.29 | 61.77 |
| Support Level | $6.49 | $43.76 |
| Resistance Level | $7.40 | $57.15 |
| Average True Range (ATR) | 0.50 | 2.39 |
| MACD | 0.21 | 0.43 |
| Stochastic Oscillator | 73.58 | 93.26 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.